NEWS ITEMS

thromboDx acquires a new EUROSTARS grant

Posted on

Amsterdam, The Netherlands – thromboDx, the molecular diagnostics company that develops and commercializes blood-based diagnostics through its proprietary platelet-powered technology platform, announces that is has received another EUROSTARS grant. Focusing on the development of companion diagnostics for therapy monitoring of lung cancer patients, thromboDx decided to lead a consortium and submit a proposal under the…

Read

All-in-one cancer diagnostics platform

Posted on

thromboDx collaborators show Blood Platelets offer all-in-one cancer diagnostics platform; study published in Cancer Cell   Amsterdam, 29th October 2015: thromboDx, a molecular diagnostic company based in Amsterdam, The Netherlands announced that a 283 subject study shows that its’ blood platelet based diagnostic platform enables accurate detection, classification and subtyping of cancer in the equivalent…

Read

thromboDx pitching at Falling Walls 2014

Posted on

Amsterdam – thromboDx announces that is has been nominated and elected to be one of the 28 young startup companies pitching at the international Falling Walls conference in Berlin on November 8 and 9. The 2014 edition of Falling Walls Conference marks the 25th anniversary of the falling of the Berlin Wall in 1989. The…

Read

Dr. Tom Würdinger awarded Galenus Prize 2014

Posted on

Dr. Tom Würdinger, Chief Scientific Officer of thromboDx was awarded the Galenus Research Prize 2014. He received the € 5,500 award and a golden medal from Dr. René Bernards, founder of biotech firm Agendia. The award ceremony took place during the Dutch Medicines Days 2014 in Ede, NL. Würdinger was selected by the jury for…

Read

We are hiring: 2x laboratory scientist

Posted on

We are hiring: 2x laboratory scientist for blood-based cancer diagnostics thromboDx BV, Amsterdam, The Netherlands thromboDx BV (www.thrombodx.com) is a molecular diagnostics company that develops and commercializes blood-based cancer diagnostics through its proprietary platelet-powered technology platform and has its offices in Amsterdam, The Netherlands. The technology platform addresses the need for an easily accessible, minimally…

Read

thromboDx acquires prestigious EUROSTARS grant

Posted on

Amsterdam, The Netherlands – thromboDx, the molecular diagnostics company that develops and commercializes blood-based diagnostics through its proprietary platelet-powered technology platform, announces that is has received a prestigious EUROSTARS grant. Focusing on the development of companion diagnostics for therapy monitoring of lung cancer patients, thromboDx decided to lead a consortium and submit a proposal under…

Read

Dr Thomas Wurdinger receives ISEV award for Best Presentation

Posted on

The platelet diagnostics platform and current assay development was awarded Best Presention of the extracellular vesicle meeting during the ISEV 2013 meeting in Boston, organised by the International Society for Extracellular Vesicles. Dr. Thomas Wurdinger received the award last Saturday. “It is a great pleasure being recognized by the microvesicle community, and to be able to…

Read

thromboDx presents latest results at ISEV 2013

Posted on

thromboDx presented their latest data on platelet powered diagnostics at the ISEV meeting in Boston.

Read

thromboDx BV succesfully incorporated

Posted on

thromboDx BV with offices in Amsterdam, The Netherlands, is succesfully incorporated. As a spin out from the VU University Medical Center (VUmc), thromboDx BV is embedded in an excellent scientific and clinical infrastructure that allows rapid access to patient cohorts and clinical studies. Medical diagnostics and oncology are key focus points of VUmc and the company…

Read

VU University and thromboDx BV sign exclusive license

Posted on

thromboDx BV and VU University, Amsterdam, The Netherlands, have signed an exclusive world-wide license agreement on the platelet-powered diagnostics patent portfolio. thromboDx BV has licensed the intellectual property rights to a broad patent portfolio covering the use of platelets as unique source of disease specific nucleic acids. The core principle of the patent portfolio is the finding…

Read